# Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

> **NCT02090725** · PHASE2 · TERMINATED · sponsor: **Jeffrey A. Cohen, MD** · enrollment: 4 (actual)

## Conditions studied

- Muscle Weakness

## Interventions

- **DRUG:** 3-4 Diaminopyridine

## Key facts

- **NCT ID:** NCT02090725
- **Lead sponsor:** Jeffrey A. Cohen, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-02
- **Primary completion:** 2018-07
- **Final completion:** 2018-11-28
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Drug receive FDA approval
- **Last updated:** 2019-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02090725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02090725, "Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02090725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*